Lactobacillus plantarum L-27-2 and its application

Abstract

The present invention provides a strain of Lactobacillus plantarum L-27-2 and an application thereof. The Lactobacillus plantarum L-27-2 of the present invention can effectively alleviate dyslipidemia, intestinal flora imbalance and weight gain caused by a high-fat diet, reduce cholesterol absorption, has a bactericidal effect on common pathogenic bacteria, can be widely used in the addition of probiotics to cat food or the preparation of health products for cats, and the strain has broad market application potential.

Description

Technical Field

[0001] The invention relates to the technical field of microorganisms, in particular to Lactobacillus plantarum L-27-2 and applications thereof. Background Art

[0002] According to statistics, about 52.8% of pet cats in my country have health problems, among which cat obesity is one of the main factors affecting cat health. During the breeding process, more and more cats become obese due to factors such as breed, age and lifestyle, which in turn causes endocrine diseases, metabolic diseases, hyperlipidemia, orthopedic diseases, cardiopulmonary diseases, reproductive disorders and other serious diseases, which seriously endanger the health of cats.

[0003] At present, the main method to improve cat obesity is to feed cats with energy-restricted diets. However, due to the difficulty in changing the inherent feeding behavior of cats and the intake of pet snacks, the weight loss effect is not obvious, and even accelerates the occurrence of various nutritional metabolic diseases. Studies have shown that changes in intestinal microorganisms may be one of the causes of obesity, and diet-mediated microbial changes can improve cat obesity to a certain extent. As a type of probiotic, a large number of studies have shown that Lactobacillus plantarum can improve obesity symptoms by acting on the lipid metabolism pathway in the body, and taking probiotics can significantly enhance the body's immune response, improve disease resistance, and reduce the incidence of diarrhea and constipation. However, among the existing probiotic products for cats, most products only have the function of regulating intestinal flora, and have no obvious effect on the cholesterol content in the body. Moreover, most of them are of human or other animal origin, and the colonization effect in the cat's intestine is unstable, which greatly weakens the therapeutic effect of the strain. Summary of the invention

[0004] The invention aims to provide Lactobacillus plantarum L-27-2 and application thereof.

[0005] In order to achieve the purpose of the present invention, in the first aspect, the present invention provides a new probiotic strain isolated from healthy cat feces - Lactobacillus plantarum L-27-2, which has been deposited in the General Microbiology Center of China Culture Collection Administration, No. 3, Yard No. 1, Beichen West Road, Chaoyang District, Beijing, Institute of Microbiology, Chinese Academy of Sciences, Postal Code 100101, Deposit Number CGMCC No.27193, Deposit Date April 24, 2023.

[0006] In a second aspect, the present invention provides a probiotic preparation, the active ingredient of which is the Lactobacillus plantarum L-27-2.

[0007] Furthermore, the probiotic preparation is a freeze-dried powder.

[0008] The freeze-drying protective agent used for preparing the freeze-dried probiotic preparation is calculated by weight percentage as follows: 1% sucrose, 1% galactose, 20% skim milk powder and 78% ddH2O.

[0009] In a specific embodiment of the present invention, the preparation method of the freeze-dried probiotic preparation of Lactobacillus plantarum L-27-2 is as follows:

[0010] After the plant lactobacillus L-27-2 is placed and cultured for 24h using MRS liquid culture medium at 37°C, centrifuged at 25°C, 6000rpm for 10min, the thalline is precipitated, and then the thalline is resuspended using ddH2O, and centrifuged at 25°C, 6000rpm for 10min again, the thalline is washed, and the plant lactobacillus L-27-2 bacterium mud is finally obtained. The lyophilization protective agent (1% sucrose, 1% galactose, 20% skim milk powder, 78% ddH2O) is homogenized, sterilized and cooled. Wherein, the sterilization condition is: 100°C sterilization for 20min. The temperature after the cooling treatment is 25°C. The plant lactobacillus L-27-2 bacterium mud after washing is added to the lyophilization protective agent after the cooling treatment, mixed, homogenized, after-80°C pre-freeze 12h, put into a freeze dryer, lyophilized at 0Pa,-80°C, to obtain the plant lactobacillus L-27-2 freeze-dried probiotic preparation.

[0011] Furthermore, the bacterial content of Lactobacillus plantarum L-27-2 in the probiotic preparation is 1.0×10 10 CFU / g-1.0×10 12 CFU / g.

[0012] In a third aspect, the present invention provides any of the following applications of the plant lactobacillus L-27-2 or the probiotic preparation:

[0013] (1) Used for the preparation of biological products for alleviating obesity;

[0014] (2) For the preparation of anti-hyperlipidemia drugs;

[0015] (3) Used to prepare biological products for improving intestinal flora;

[0016] (4) Used for preparing lipid-lowering foods;

[0017] (5) Used in the preparation of animal feed;

[0018] (6) Used to treat obesity in cats;

[0019] (7) Used to treat feline metabolic syndrome;

[0020] (8) Used to lower blood lipids in cats.

[0021] In a fourth aspect, the present invention provides a medicine for alleviating obesity in cats, wherein the effective ingredient of the medicine is the Lactobacillus plantarum L-27-2 or the probiotic system.

[0022] In a fifth aspect, the present invention provides the use of the Lactobacillus plantarum L-27-2 in the preparation of a fungicide.

[0023] The bacteria include but are not limited to Escherichia coli, Salmonella, and Staphylococcus aureus.

[0024] By means of the above technical solution, the present invention has at least the following advantages and beneficial effects:

[0025] (1) The plant lactobacillus L-27-2 of the present invention can effectively alleviate dyslipidemia, intestinal flora imbalance and weight gain caused by a high-fat diet, reduce cholesterol absorption, and has a bactericidal effect on common pathogenic bacteria. It can be widely used in the addition of probiotics to cat food or the preparation of health products for cats. The strain has broad market application potential.

[0026] (ii) The results of the acid resistance experiment showed that Lactobacillus plantarum L-27-2 grew well in an environment with a pH of 3, and the viable bacterial count survival rate after 4 hours in an acidic environment with a pH of 2 was 91%, indicating that the strain can tolerate the acidic environment well, can tolerate the gastrointestinal environment well, and can reach the intestine to exert its biological effects.

[0027] (III) The results of the antibacterial test showed that Lactobacillus plantarum L-27-2 could inhibit Escherichia coli, Salmonella and Staphylococcus aureus (inhibition zone R = 0-2 cm).

[0028] (IV) The results of drug resistance experiments showed that nine commonly used antibiotics in clinical practice, including erythromycin, ceftriaxone, cefuroxime, and ampicillin, could effectively inhibit the growth of Lactobacillus plantarum L-27-2, indicating that the strain had no drug resistance and could be safely used in clinical practice. BRIEF DESCRIPTION OF THE DRAWINGS

[0029] Figure 1 This is a phylogenetic tree diagram of the Lactobacillus plantarum CGMCC NO.27193 strain in Example 1 of the present invention.

[0030] Figure 2 This is a graph showing the acid resistance of the Lactobacillus plantarum CGMCC NO.27193 strain in Example 2 of the present invention.

[0031] Figure 3 This is a graph showing the weight changes of mice induced by the Lactobacillus plantarum CGMCC NO.27193 strain in Example 4 of the present invention.

[0032] Figure 4This is a graph showing changes in total cholesterol content in mouse liver induced by Lactobacillus plantarum CGMCC NO.27193 strain in Example 4 of the present invention.

[0033] Figure 5 This is a graph showing changes in serum LDL-C levels in mice induced by the Lactobacillus plantarum CGMCC NO.27193 strain in Example 4 of the present invention.

[0034] Figure 6 This is a graph showing changes in the obesity index of mice induced by the Lactobacillus plantarum CGMCC NO.27193 strain in Example 4 of the present invention.

[0035] Figure 7 This is a real picture of the liver lesions in mice caused by the Lactobacillus plantarum CGMCC NO.27193 strain in Example 4 of the present invention.

[0036] Figure 8 This is a pathological section of mouse adipose tissue lesions caused by Lactobacillus plantarum CGMCC NO.27193 strain in Example 4 of the present invention. DETAILED DESCRIPTION

[0037] In view of the many problems existing in the existing lactic acid bacteria and probiotic products for cats used to regulate cat obesity, the present invention aims to provide a cat-derived Lactobacillus plantarum CGMCC NO.27193 strain that can alleviate obesity induced by a high-fat diet, and prepare the Lactobacillus plantarum CGMCC NO.27193 into a freeze-dried probiotic preparation for the development of drugs or health products for relieving cat obesity. The strain has high strain activity after freeze-drying, has a strong inhibitory effect on common clinical pathogens of cats, can tolerate gastric acid environment, can effectively increase cholesterol metabolism in obese animals, and can be used clinically to reduce the occurrence of cat obesity.

[0038] The present invention adopts the following technical solution:

[0039] The invention separates a new probiotic strain L-27-2 from healthy cat feces, and identifies the strain as Lactobacillus plantarum through microbiological property analysis and 16S rRNA gene sequence (SEQ ID NO: 1) comparative analysis.

[0040] Through the acid resistance experiment, it was found that the plant lactobacillus CGMCC NO.27193 grew well in an environment with a pH of 3, and the viable bacteria count survival rate after 4 hours in an acidic environment with a pH of 2 was 91%, indicating that the plant lactobacillus CGMCC NO.27193 provided by the present invention can tolerate the acidic environment well, can better tolerate the gastrointestinal environment, and can reach the intestine to exert biological effects.

[0041] It was found through antibacterial tests that the plant lactobacillus CGMCC NO.27193 can produce an inhibitory effect on Escherichia coli, Salmonella and Staphylococcus aureus (inhibition zone R=0-2 cm).

[0042] Through drug resistance experiments, it was found that nine commonly used antibiotics in clinical practice, including erythromycin, ceftriaxone, cefuroxime, ampicillin, etc., can effectively inhibit the growth of Lactobacillus plantarum CGMCC NO.27193, indicating that Lactobacillus plantarum CGMCC NO.27193 has no drug resistance and can be safely used in clinical practice.

[0043] The invention also provides application of Lactobacillus plantarum CGMCC NO.27193 in preparing medicine or health care product for alleviating obesity induced by high-fat diet.

[0044] Furthermore, Lactobacillus plantarum CGMCC NO.27193 is added with additives acceptable in food science to prepare a freeze-dried probiotic preparation of Lactobacillus plantarum CGMCC NO.27193.

[0045] Specifically, the freeze-drying protective agent components of the Lactobacillus plantarum CGMCC NO.27193 freeze-dried probiotic preparation are 1% sucrose, 1% galactose, 20% skim milk powder, and 78% ddH2O.

[0046] Specifically, the Lactobacillus plantarum CGMCC NO.27193 freeze-dried probiotic preparation is prepared by mixing Lactobacillus plantarum CGMCC NO.27193 freeze-dried powder and the freeze-drying protective agent in a ratio of 1:8.

[0047] Specifically, the content of Lactobacillus plantarum CGMCC NO.27193 in the freeze-dried probiotic preparation of Lactobacillus plantarum CGMCC NO.27193 is 1.0×10 12 CFU / g, based on the total weight of the freeze-dried Lactobacillus plantarum preparation, the total weight of the Lactobacillus plantarum CGMCC NO.27193 is 12.5%.

[0048] The present invention further verifies through a mouse high-fat diet model that the Lactobacillus plantarum CGMCC NO.27193 freeze-dried probiotic preparation has a good effect in alleviating obesity caused by a high-fat diet.

[0049] Specifically, in the high-fat diet model of mice, the freeze-dried probiotic preparation of Lactobacillus plantarum CGMCC NO.27193 can significantly alleviate the weight gain and abdominal fat accumulation of mice, and can reduce the LDL-C content in the high-fat diet model of mice, which is different from the LDL-C content in the high-fat diet model of mice fed with PBS.

[0050] The probiotic preparation can be prepared by using the plant lactobacillus CGMCC NO.27193 of the present invention, and the probiotic preparation contains the live bacteria of plant lactobacillus CGMCC NO.27193. The probiotic preparation of the present invention can be capsules, solutions or bagged powders. Each single dose generally contains 1.0×10 plant lactobacillus CGMCC NO.27193 strains. 10 CFU / g-1.0×10 12 The probiotic preparation of the present invention can be used to prevent and treat obesity caused by a high-fat diet.

[0051] Preferably, the probiotic preparation is an oral preparation.

[0052] The plant lactobacillus CGMCC NO.27193 of the invention can also be prepared into food and food ingredients for preventing the occurrence of obesity in cats.

[0053] The following examples are used to illustrate the present invention, but are not intended to limit the scope of the present invention. Unless otherwise specified, the technical means used in the examples are conventional means well known to those skilled in the art, and the raw materials used are all commercially available products.

[0054] Example 1 Screening, Isolation and Identification of Lactobacillus plantarum L-27-2

[0055] 1. Screening and isolation of strain L-27-2

[0056] Fecal samples from 85 healthy cats were collected and inoculated into MRS liquid culture medium. After culturing at 37°C for 24 h, the samples were diluted to 10% with PBS. 6 The plates were spread on MRS medium respectively, and the coated plates were incubated at 37°C for 24 hours. Colonies with obvious hydrolysis zones were selected and inoculated into MRS liquid medium for amplification. They were then streaked on MRS solid medium for isolation and purification, and incubated at 37°C for 24 hours.

[0057] 2. Strain identification

[0058] The isolated and purified single colonies were subjected to Gram staining and microscopic examination. After being confirmed as single bacteria, they were frozen at -80°C with glycerol. The lactic acid bacteria genomic DNA was extracted using a bacterial genome extraction kit, and the 16S rDNA universal primers 27F and 1492R were used to amplify the target fragments. The purified and recovered PCR products were sent to Sangon Biotechnology Co., Ltd. for sequence determination. The sequencing results were compared using BLAST homology on the NCBI website. The nucleic acid sequence of the lactic acid bacteria model strain with the highest homology was selected for homology analysis, and a phylogenetic tree was constructed using the neighbor-joining method (NJ). Combining the biological characteristics and the comparison of the 16S rRNA gene sequence (SEQ ID NO: 1), the L-27-2 strain was confirmed to be Lactobacillus plantarum. The phylogenetic tree is shown in the figure below. Figure 1 shown.

[0059] The Lactobacillus plantarum L-27-2 strain was deposited in the Chinese Microbiological Culture Collection, Institute of Microbiology, Chinese Academy of Sciences, with the deposit number CGMCC No: 27193.

[0060] Example 2 Detection of characteristics of Lactobacillus plantarum CGMCC NO.27193

[0061] 1. Acid resistance test

[0062] The pH of MRS liquid culture medium was adjusted to 2, 3, and 4, respectively. Lactobacillus plantarum CGMCC NO.27193 was inoculated into the culture medium at an inoculum size of 0.01% and cultured for 2 and 4 hours. Then, solid culture medium was inoculated and cultured at 37° C. for 24 hours. The number of viable bacteria was calculated using the plate count method to determine the acid resistance of Lactobacillus plantarum CGMCC NO.27193.

[0063] The acid resistance of Lactobacillus plantarum CGMCC NO.27193 strain is as follows Figure 2 As shown, the survival rate of Lactobacillus plantarum CGMCC NO.27193 strain in an environment of pH = 2 is as high as 91%, and it grows well in an environment of pH = 3, indicating that Lactobacillus plantarum CGMCC NO.27193 strain can tolerate the acidic environment in the stomach.

[0064] 2. Antibacterial property detection

[0065] Lactobacillus plantarum CGMCC NO.27193 in the logarithmic growth phase was diluted with saline to a concentration of 10 8 CFU / mL of bacterial solution, the agar diffusion Oxford cup method was used to detect the antibacterial effect of lactic acid bacteria strains on Staphylococcus aureus, Salmonella, and Escherichia coli. The broth medium was sterilized and cooled to 50°C. 10 μL of bacterial solution (10 8CFU / mL) per 1ml of culture medium, mix well and pour into the culture medium. Add 200μL of the single strain test solution to the Oxford cup and culture at 37℃ for 24h. The radius of the inhibition zone is used as an indicator to divide it into three types: no inhibition (0cm), inhibition (0-2.0cm), and obvious inhibition (>2.0cm). The antibacterial effect of Lactobacillus plantarum CGMCC NO.27193 on Staphylococcus aureus, Salmonella, and Escherichia coli is tested respectively.

[0066] The antibacterial results of Lactobacillus plantarum CGMCC NO.27193 strain are shown in Table 1. Lactobacillus plantarum CGMCC NO.27193 strain has an inhibitory effect on Staphylococcus aureus, Salmonella and Escherichia coli.

[0067] Table 1 Antibacterial results of Lactobacillus plantarum CGMCC NO.27193 strain

[0068]

[0069] 3. Antibiotic sensitivity testing

[0070] The disc diffusion test (KB method) was used to determine whether Lactobacillus plantarum CGMCC NO.27193 was sensitive to common antibacterial drugs for cats such as Suno, Ceftiofur, Cefquinome, and Doxycycline according to the size of the inhibition ring. Under sterile conditions, a single colony was picked with a sterilized inoculation loop and inoculated in MRS medium at 37°C for 24 hours. Each plate was coated with 100 μL of bacterial solution and dropped on the surface of MRS solid medium. After uniform coating, the drug-containing paper was taken out with sterile tweezers and attached to the surface of the medium. After a period of rest, it was placed in a 37°C incubator for 24 hours. The antibacterial results were observed and the diameter of the inhibition ring of each tablet group was measured with a vernier caliper. The average value was calculated using EXCEL software. At the same time, according to the "Antimicrobial Drug Sensitivity Test Specification", the drug sensitivity effect was judged, and the results were divided into three types: resistant, intermediate (resistant intermediate sensitive), and sensitive, to detect the antibiotic sensitivity characteristics of Lactobacillus plantarum CGMCC NO.27193.

[0071] The antibiotic sensitivity results of Lactobacillus plantarum CGMCC NO.27193 strain are shown in Table 2, indicating that Lactobacillus plantarum CGMCC NO.27193 strain is sensitive to common clinical antibiotics for cats and can be safely used in clinical practice.

[0072] Table 2 Antibiotic sensitivity results of Lactobacillus plantarum CGMCC NO.27193 strain

[0073]

[0074] Example 3 Preparation of freeze-dried probiotic preparation of Lactobacillus plantarum CGMCC NO.27193 strain

[0075] The cat-derived Lactobacillus plantarum CGMCC NO.27193 strain freeze-dried probiotic preparation is a microbial freeze-dried powder, and the freeze-dried powder is a composition of Lactobacillus plantarum CGMCC NO.27193 and galactose, sucrose and skimmed milk powder.

[0076] In the method for preparing the sludge of Lactobacillus plantarum CGMCC NO.27193, the liquid fermentation environment is: temperature 37°C, humidity 65-70%, pH value <7.

[0077] In the preparation method of the freeze-dried probiotic preparation of Lactobacillus plantarum CGMCC NO.27193, a Lactobacillus plantarum freeze-drying protective agent is used.

[0078] The plant lactobacillus freeze-dried protective agent is composed of 1% sucrose, 1% galactose, 20% skimmed milk powder and 78% ddH2O according to weight percentage.

[0079] The preparation method of the Lactobacillus plantarum CGMCC NO.27193 freeze-dried probiotic preparation is as follows:

[0080] After the plant lactobacillus CGMCC NO.27193 was placed in MRS liquid medium at 37°C for 24h, centrifuged at 6000rpm, 25°C, and 10min to precipitate the cell, and then ddH2O was used to resuspend the cell, and the cell was washed by centrifugation at 6000rpm, 25°C, and 10min to finally obtain the plant lactobacillus CGMCC NO.27193 bacterial strain mud. The lyophilization protective agent (1% sucrose, 1% galactose, 20% skim milk powder, 78% ddH2O) was homogenized, sterilized, and cooled, and the sterilization was carried out at 100°C for 20min, and the temperature after the cooling was 25°C. The washed Lactobacillus plantarum CGMCC NO.27193 strain sludge was added to the cooled lyophilization protective agent at a weight ratio of sludge: lyophilization protective agent = 1:8, mixed and homogenized, and placed at -80°C for pre-freezing for 12 hours, and then placed in a freeze dryer for freeze drying at 0 Pa and -80°C to obtain the Lactobacillus plantarum CGMCC NO.27193 freeze-dried probiotic preparation.

[0081] Example 4 Evaluation of the ability of Lactobacillus plantarum CGMCC NO.27193 to alleviate obesity in a high-fat diet model in mice

[0082] In this example, a high-fat diet was used to evaluate the lipid-lowering ability of Lactobacillus plantarum CGMCC NO.27193.

[0083] (1) Preparation of bacterial powder

[0084] The activated Lactobacillus plantarum CGMCC NO.27193 was statically cultured in MRS liquid medium at 37°C for 24h, and centrifuged at 6000rpm, 25°C, for 10min to obtain the bacteria. 1% sucrose, 1% galactose, 20% skim milk powder, and 78% ddH2O were used as freeze-drying protective agents. The bacteria were resuspended in a weight ratio of bacterial mud: freeze-drying protective agent = 1:8, and then pre-frozen at -80°C for 12h, and then placed in a freeze dryer for freeze-drying at 0Pa, -80°C. After the freeze-drying was completed, the number of live bacteria in the freeze-dried powder was calculated by the coating plate counting method.

[0085] (2) Experimental feeding and grouping

[0086] Nine healthy 4-week-old Babl / c male mice were selected and randomly divided into L-27-2 group, model group and blank control group, with 3 mice in each group and 3 mice in each cage. After 3 days of adaptation to feeding with ordinary breeding feed, L-27-2 group and model group were fed HFD feed, and blank control group was fed with ordinary mouse breeding feed. At the same time, L-27-2 group was gavaged with the freeze-dried probiotic preparation of Lactobacillus plantarum CGMCCNO.27193 for 28 consecutive days, with a gavage dose of 0.1 mL (1×10 9 CFU / mouse / day). The model group and the blank control group were gavaged with 0.1mL PBS. The environment was (22±2℃), humidity was 30-70%, and the mice were free to eat and drink water. At the end of the experiment, the mice were killed by dislocating the neck after blood was collected from the eyeballs. The organs were dissected and the amount of abdominal fat accumulation, liver cholesterol content, and serum lipid metabolism-related protein expression of the mice were recorded and observed. The ability of Lactobacillus plantarum CGMCC NO.27193 to alleviate obesity was evaluated.

[0087] (3) Weight monitoring

[0088] During the experiment, the body weight of mice was observed and recorded every 3 days, and the differences among the probiotic group, model group and control group were compared.

[0089] Weight results are as follows Figure 3 As shown, it can be found that the body weight of mice fed with the freeze-dried probiotic preparation of Lactobacillus plantarum CGMCC NO.27193 for 28 days was significantly different from that of the model group (P < 0.05), and was similar to that of the blank control group.

[0090] (4) Determination of total cholesterol and lipid metabolism-related proteins

[0091] At the end of the experiment, the mice were enucleated and blood was collected. After the blood was collected, it was kept at room temperature for 10 minutes and centrifuged at 4000rpm for 1 minute to separate the serum. The mouse liver was removed after autopsy, 0.1g was weighed and added to 9mL of anhydrous ethanol, and the supernatant was taken for detection after homogenization. The total cholesterol (TC) in the mouse liver and the LDL-C (low-density lipoprotein cholesterol) content in the mouse serum were determined using a kit.

[0092] The results are as follows Figure 4 , Figure 5 As shown, it can be found that the total cholesterol content in the liver of mice fed with the freeze-dried probiotic preparation of Lactobacillus plantarum CGMCC NO.27193 for 28 days was significantly reduced (P < 0.05), and the LDL-C content in the serum was lower than that in the model group (P > 0.05).

[0093] (5) Changes in obesity index

[0094] After autopsy, remove abdominal fat from mice, rinse with sterile saline, dry with filter paper, weigh and calculate obesity index, and record the difference:

[0095] Obesity index = (abdominal fat weight / body weight) × 100

[0096] Obesity index results are as follows Figure 6 As shown, the obesity index of mice fed with the freeze-dried probiotic preparation of Lactobacillus plantarum CGMCC NO.27193 was lower than that of mice fed only with a high-fat diet (P>0.05).

[0097] (6) Liver lesions

[0098] The mouse livers were removed after autopsy, and the appearance of the livers of mice in different groups was observed with the naked eye.

[0099] Liver picture Figure 7 As shown, the liver condition of mice fed with freeze-dried probiotic preparation of Lactobacillus plantarum CGMCC NO.27193 was better than that of the model group.

[0100] (7) Fatty lesions

[0101] After autopsy, the abdominal fat of the mice was removed, and the adipose tissue was fixed with 4% tissue fixative at a volume 5-10 times that of the fat, and pathological sections were made to observe tissue changes.

[0102] The test results are as follows Figure 8 As shown, it can be found that the proliferation and hypertrophy of abdominal adipocytes in mice fed with the freeze-dried probiotic preparation of Lactobacillus plantarum CGMCC NO.27193 is less than that in mice fed only with a high-fat diet, only a small number of inflammatory cells are seen, and there are no necrotic foci of adipocytes.

[0103] Although the present invention has been described in detail above with general descriptions and specific embodiments, it is obvious to those skilled in the art that some modifications or improvements can be made based on the present invention. Therefore, these modifications or improvements made without departing from the spirit of the present invention all fall within the scope of protection claimed by the present invention.

Claims

1. Lactobacillus plantarum Lactobacillus plantarum L-27-2, characterized in that The deposit number is CGMCC No. 27193.

2. A probiotic preparation, characterized in that: The active ingredient is the Lactobacillus plantarum L-27-2 described in claim 1.

3. The probiotic preparation according to claim 2, characterized in that It is a freeze-dried powder; The freeze-drying protective agents used were calculated by weight percentage as follows: 1% sucrose, 1% galactose, 20% skimmed milk powder and 78% ddH2O.

4. The probiotic preparation according to claim 2 or 3, characterized in that: The bacterial content of Lactobacillus plantarum L-27-2 was 1.0×10 10 CFU / g-1.0×10 12 CFU / g.

5. Any of the following uses of the Lactobacillus plantarum L-27-2 of claim 1 or the probiotic preparation of any one of claims 2 to 4: (1) Used for the preparation of biological products for alleviating obesity; (2) Used for the preparation of anti-hyperlipidemia drugs; (3) Used to prepare biological products for improving intestinal flora; (4) Used in the preparation of lipid-lowering foods; (5) Used in the preparation of animal feed.

6. Use of the plant lactobacillus L-27-2 according to claim 1 in the preparation of a fungicide; The bacteria are selected from Escherichia coli, Salmonella and Staphylococcus aureus.

Images